GSK to invest $800 million in Pennsylvania biologics manufacturing hub

GSK is investing over $800 million to transform its Upper Merion, Pennsylvania site into a biopharmaceutical manufacturing and R&D hub, bringing its total planned state investment to nearly $1.7 billion. The project will feature a commercial biologics plant, an R&D pilot plant, and a quality control lab focused on cancer and respiratory treatments. Construction begins in 2027, creating over 300 jobs and retaining 4,500 existing roles while utilizing state tax incentives.

Upper Merion expansion plans

• ▪GSK is investing more than $800 million to expand its site in Upper Merion Township, Pennsylvania into a biopharmaceutical manufacturing and research hub.
• ▪The Upper Merion expansion forms part of a broader $1.2 billion investment by GSK earmarked for advanced manufacturing, artificial intelligence, and digital technologies.
• ▪Construction on the GSK Upper Merion expansion is planned to begin in 2027 and will involve demolishing existing buildings to make way for new facilities.

Planned facilities at Upper Merion

• ▪The GSK Upper Merion project includes a co-located research and development pilot plant designed to accelerate technology transfer and process development.
• ▪The GSK Upper Merion project includes a new commercial-scale biologics manufacturing facility to support both clinical and commercial production of biologic medicines.
• ▪GSK's Upper Merion Next Generation Flex Factory will focus on manufacturing potential best-in-class medicines for respiratory disease and cancer.
• ▪The GSK Upper Merion hub will construct a centralized quality control laboratory and a manufacturing science and technology hub.

Employment impact in Pennsylvania

• ▪The GSK Upper Merion expansion project will retain approximately 4,500 existing full-time GSK jobs across Pennsylvania.
• ▪The GSK Upper Merion site expansion is expected to create more than 300 new jobs over the next five years.

Pennsylvania state tax incentives

• ▪Pennsylvania has previously used manufacturing tax incentives to attract biopharmaceutical investments from companies including Eli Lilly and Johnson & Johnson.
• ▪GSK will be eligible for Pennsylvania state manufacturing tax incentives, including the Qualified Manufacturing Innovation and Reinvestment Deduction program and the Manufacturing Tax Credit initiative.

GSK expansion in Marietta

• ▪Together with a previously announced $800 million expansion in Marietta, Pennsylvania, GSK's Upper Merion project represents nearly $1.7 billion of planned investment in the state.
• ▪GSK plans to debut a new drug substance facility in Marietta, Pennsylvania by the end of 2027, followed by a drug product facility slated for operation in 2028.